| Dr Syed Raza Jafri, MD | |
|
7900 Cambridge St, # 22-2d, Houston, TX 77054-5502 | |
| (832) 748-2067 | |
| Not Available |
| Full Name | Dr Syed Raza Jafri |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 20 Years |
| Location | 7900 Cambridge St, Houston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174876692 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | P3542 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bristol Hospice - Texas Llc | The woodlands, TX | Hospice |
| Harbor Hospice 28 Lp | Conroe, TX | Hospice |
| Huntsville Memorial Hospital | Huntsville, TX | Hospital |
| Hca Houston Healthcare Conroe | Conroe, TX | Hospital |
| Avalon Place Trinity | Trinity, TX | Nursing home |
| Huntsville Health Care Center | Huntsville, TX | Nursing home |
| Entity Name | Corpus Christi Hospitalists, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518052190 PECOS PAC ID: 3779585278 Enrollment ID: O20070213000489 |
News Archive
Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.
Research commissioned by Innovate UK and the British In Vitro Diagnostics Association reveals that the NHS could save over £6.9 billion in five years through quick adoption of new diagnostic tests as they come onto the market. In turn, these savings could help tackle the annual NHS shortfall, widely expected to reach £20 billion by 2022.
A new study has found a "significant association" between adults who have suffered a traumatic brain injury at some point in their lives and who also have attention deficit hyperactive disorder.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.
› Verified 9 days ago
| Entity Name | Hospital Docs Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871792309 PECOS PAC ID: 7517052822 Enrollment ID: O20071002000420 |
News Archive
Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.
Research commissioned by Innovate UK and the British In Vitro Diagnostics Association reveals that the NHS could save over £6.9 billion in five years through quick adoption of new diagnostic tests as they come onto the market. In turn, these savings could help tackle the annual NHS shortfall, widely expected to reach £20 billion by 2022.
A new study has found a "significant association" between adults who have suffered a traumatic brain injury at some point in their lives and who also have attention deficit hyperactive disorder.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.
› Verified 9 days ago
| Entity Name | Raza Jafri Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275196164 PECOS PAC ID: 5395088355 Enrollment ID: O20190515002631 |
News Archive
Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.
Research commissioned by Innovate UK and the British In Vitro Diagnostics Association reveals that the NHS could save over £6.9 billion in five years through quick adoption of new diagnostic tests as they come onto the market. In turn, these savings could help tackle the annual NHS shortfall, widely expected to reach £20 billion by 2022.
A new study has found a "significant association" between adults who have suffered a traumatic brain injury at some point in their lives and who also have attention deficit hyperactive disorder.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.
› Verified 9 days ago
| Entity Name | Internist Chronic Care Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285199448 PECOS PAC ID: 2769715705 Enrollment ID: O20190606002239 |
News Archive
Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.
Research commissioned by Innovate UK and the British In Vitro Diagnostics Association reveals that the NHS could save over £6.9 billion in five years through quick adoption of new diagnostic tests as they come onto the market. In turn, these savings could help tackle the annual NHS shortfall, widely expected to reach £20 billion by 2022.
A new study has found a "significant association" between adults who have suffered a traumatic brain injury at some point in their lives and who also have attention deficit hyperactive disorder.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.
› Verified 9 days ago
| Entity Name | Hha Hospital Medicine Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083489967 PECOS PAC ID: 7618329079 Enrollment ID: O20240122001831 |
News Archive
Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.
Research commissioned by Innovate UK and the British In Vitro Diagnostics Association reveals that the NHS could save over £6.9 billion in five years through quick adoption of new diagnostic tests as they come onto the market. In turn, these savings could help tackle the annual NHS shortfall, widely expected to reach £20 billion by 2022.
A new study has found a "significant association" between adults who have suffered a traumatic brain injury at some point in their lives and who also have attention deficit hyperactive disorder.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Syed Raza Jafri, MD 7900 Cambridge Street, # 22-2d, Houston, TX 77054 Ph: (832) 748-2067 | Dr Syed Raza Jafri, MD 7900 Cambridge St, # 22-2d, Houston, TX 77054-5502 Ph: (832) 748-2067 |
News Archive
Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.
Research commissioned by Innovate UK and the British In Vitro Diagnostics Association reveals that the NHS could save over £6.9 billion in five years through quick adoption of new diagnostic tests as they come onto the market. In turn, these savings could help tackle the annual NHS shortfall, widely expected to reach £20 billion by 2022.
A new study has found a "significant association" between adults who have suffered a traumatic brain injury at some point in their lives and who also have attention deficit hyperactive disorder.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.
› Verified 9 days ago
Dr. Jeanette Ferrer, D.O Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6565 Fannin St., Main 577, Houston, TX 77030 Phone: 713-441-0428 | |
Dr. Bhavik Kumar, MD, MPH Family Medicine Medicare: Medicare Enrolled Practice Location: 4600 Gulf Fwy, Houston, TX 77023 Phone: 713-522-3976 Fax: 404-494-7435 | |
Nneka Okafor, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3701 Kirby Dr Ste 600, Houston, TX 77098 Phone: 713-798-8072 | |
Dr. Rolando R Maldonado I, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 548 Waugh Dr, Houston, TX 77019 Phone: 713-933-0501 | |
Scott H Hung, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 10950 Resource Pkwy, Suite A, Houston, TX 77089 Phone: 281-484-5587 Fax: 281-506-1013 | |
Michael E. Buxbaum, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3100 Weslayan St Ste 350, Houston, TX 77027 Phone: 713-533-1700 Fax: 713-533-1708 | |
Diana Atwal, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6630 De Moss Dr, Houston, TX 77074 Phone: 713-272-2600 Fax: 713-272-5589 |